AmeriHealth Caritas has worked to facilitate vaccine accessibility from adults to the Medicaid managed care organization's youngest members.
The organization and its respective plans have orchestrated efforts across plans to create better vaccine access for all individuals, including partnering with local governments to use AmeriHealth Caritas locations as vaccination sites and hosting COVID-19 vaccination events within local communities.
The FDA-authorized bivalent boosters include protection from Omicron subvariants, BA.4 and BA.5, and are available for children as young as six months old.
Bivalent boosters are approved for all children ages six months and up, regardless of which company manufactured their primary vaccine series.
AmeriHealth Caritas encourages everyone to ask their COVID-19 vaccine provider or pharmacist which kind of vaccine and how many doses they and their family members will need especially as recommendations continue to adjust.
For infants and children who are moderately or severely immunocompromised or have unique conditions, it is best to speak with their provider for specific vaccination guidance.
The CDC website states that COVID-19 vaccines and boosters are safe to administer at the same time as flu or other vaccines, reducing the travel and appointment burden for families.
Annual flu shots are available for children as young as six months and can be received anytime through the winter during the flu season.
AmeriHealth Caritas operates in 12 states and the District of Columbia.
AmeriHealth Caritas serves approximately 5m Medicaid, Medicare, Children's Health Insurance Program, and Health Insurance Marketplace members through its integrated managed care products, pharmaceutical benefit management and specialty pharmacy services, and behavioral health services.
Headquartered in Pennsylvania, AmeriHealth Caritas is a mission-driven organization with nearly 40 years of experience serving low-income and chronically ill populations.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine